Analysis of data from the Russian AURA registry (real-world data registry on AlbUminuRia detection rate among patients with previously undiAgnosed chronic kidney disease)

Autor: M. M. Batyushin, M. A. Trubnikova, G. P. Arutyunov, E. I. Tarlovskaya, A. G. Arutyunov, D. S. Polyakov, S. Sh. Akhmedkhanov, I. G. Bakulin, I. A. Bodrievskaya, I. A. Viktorova, N. G. Vinogradova, A. S. Galyavich, N. P. Garganeeva, N. Yu. Grigorieva, S. B. Erofeeva, M. A. Kercheva, S. G. Kechedzhieva, N. A. Koryagina, S. V. Malchikova, V. A. Nevzorova, S. V. Nedogoda, M. M. Petrova, V. A. Pogrebetskaya, A. P. Rebrov, O. A. Rubanenko, E. A. Safianik, V. V. Skibitsky, E. A. Smirnova, E. A. Starovoitova, R. F. Khamitov, A. I. Chesnikova, T. M. Shabatina, I. I. Shaposhnik, A. R. Vaisberg, A. V. Aparkina, I. N. Barykina, T. I. Batluk, R. A. Bashkinov, A. T. Beybalayeva, Y. A. Belenikina, O. A. Bilevich, Zh. V. Bondareva, A. Yu. Vaskin, T. V. Vlasova, E. V. Galko, T. U. Garifullin, E. D. Gordeychuk, E. V. Grigorieva, I. V. Gubareva, L. K. Danilova, A. I. Dolgushina, E. M. Durygina, D. S. Evdokimov, N. V. Zhdankina, E. I. Zheleznyak, D. S. Zueva, D. S. Ivanova, E. Yu. Ivanchenko, M. V. Kazakovtseva, A. A. Kaznina, N. A. Karoli, D. S. Kaskaeva, Z. F. Kim, M. V. Kozlova, Y. I. Kudrinskaya, A. S. Kuznetsova, E. Yu. Levchenko, I. A. Lukonin, V. O. Lutova, N. A. Magdeeva, E. V. Makarova, N. E. Makarova, M. M. Mamontova, E. S. Melnikov, A. F. Molostvova, T. D. Naborshchikova, I. N. Nikitina, D. P. Novikova, M. V. Novikova, V. I. Pakusina, K. G. Pereverzeva, I. S. Pleshakov, Yu. G. Pokramovich, O. V. Ponomareva, E. A. Popova, N. A. Popova, E. S. Potapova, E. D. Resnyanskaya, M. Yu. Rozhkova, A. O. Rubanenko, M. D. Rudoy, A. S. Salasyuk, L. M. Salimova, V. I. Samokhina, N. Sh. Sanginova, F. I. Sattarova, A. Kh. Safina, D. P. Sirotenko, N. S. Skarzhinskaya, A. V. Skibitsky, E. I. Suchkova, L. E. Tepnadze, A. V. Fendrikova, T. E. Filatova, O. V. Filyushin, O. Yu. Chizhova, T. I. Chudinovskikh, S. S. Yakushin, E. M. Yashina

Publikováno v: Российский кардиологический журнал, Vol 29, Iss 7 (2024)

Aim. To present data from the AURA Registry (real-world data registry on AlbUminuRia detection rate among patients with previously undiAgnosed chronic kidney disease). It is important to perform population studies both to study the occurrence of mark

Externí odkaz: https://doaj.org/article/e6737166623e4811afc3782016a90baa

Relationships and Activities. The study is supported by OOO AstraZeneca Phar­maceuticals.

Autor: E. V. Shlyakhto, Yu. N. Belenkov, S. I. Boytsov, S. V. Villevalde, A. S. Galyavich, M. G. Glezer, N. E. Zvartau, Zh. Kobalava, Yu. M. Lopatin, Yu. V. Mareev, S. N. Tereshchenko, I. V. Fomin, O. L. Barbarash, N. G. Vinogradova, D. V. Duplyakov, I. V. Zhirov, E. D. Kosmacheva, V. A. Nevzorova, O. M. Reitblat, A. E. Soloveva, E. A. Zorina

Publikováno v: Российский кардиологический журнал, Vol 28, Iss 6 (2023)

Heart failure (HF) is a global health problem. Despite advances in the development of effective treatments for patients with heart failure, morbidity and mortality from remain high, and the prognosis is poor. However, there is potential to improve ou

Externí odkaz: https://doaj.org/article/81e00cc515b145e79cd24023bb440836

The Effects of Telmisartan and Its Combinations on Office Blood Pressure: Results of Prospective Observational Study TAINA

Autor: O. D. Ostroumova, A. I. Kochetkov, F. T. Ageev, G. S. Anikin, E. Kh. Akhmetzyanova, E. I. Bezuglova, A. B. Bekoeva, N. Yu. Borovkova, N. G. Vinogradova, E. V. Gorbunova, A. A. Goryacheva, E. S. Zhugrova, O. A. Kislyak, S. M. Klyashev, V. P. Kuzmin, A. A. Lipchenko, G. V. Matyushin, E. A. Mikhailova, V. A. Nevzorova, A. G. Obrezan, T. A. Petrichko, M. M. Petrova, A. N. Reider, A. N. Repin, V. I. Sadovoy, N. P. Sanina, A. E. Skripchenko, R. I. Stryuk, I. V. Faiyance, L. A. Khaisheva, N. R. Khasanov, R. A. Khokhlov, E. E. Tsareva, A. L. Cherkashina, I. I. Shaposhnik, I. A. Shelestova, R. N. Shepel, E. V. Shikh, D. A. Yakhontov

Publikováno v: Рациональная фармакотерапия в кардиологии, Vol 16, Iss 2, Pp 175-190 (2020)

Aim. To evaluate the effectiveness and safety of telmisartan, used in monotherapy or in combination with hydrochlorothiazide or amlodipine, in real clinical practice in patients with diagnosed arterial hypertension who have not reached the target lev

Externí odkaz: https://doaj.org/article/9a89b6f41c844d00b164e671e6fe74c3

Resolution of an online meeting of the Volga Federal District experts on the EMPEROR-Reduced trial 'A new era in the treatment of patients with HF. From EMPA-REG OUTCOME to EMPEROR-Reduced trial'

Autor: S. V. Villevalde, A. S. Galyavich, N. G. Vinogradova, E. N. Volodina, I. R. Gaisin, S. R. Gilyarevsky, L. V. Grekhova, Yu. A. Guryanova, P. S. Guseva, D. V. Duplyakov, A. V. Ezhov, N. E. Zakirova, Yu. V. Zolotova, A. V. Isakov, S. V. Kanysheva, Z. F. Kim, V. P. Kuzmin, S. S. Markiyanova, S. A. Pomosov, A. P. Rebrov, E. I. Tarlovskaya, S. N. Tolstov, I. V. Fomin, N. R. Khasanov, A. M. Shutov

Publikováno v: Российский кардиологический журнал, Vol 26, Iss 2S (2021)

An online meeting of experts held on November 6, 2020 describes the results of EMPA-REG OUTCOME and EMPEROR-Reduced trials on sodium-glucose co-transporter-2 (SGLT2) inhibitor empagliflozin. We analyzed cardiovascular and renal outcomes in patients w

Externí odkaz: https://doaj.org/article/280165940e9842ad9ebdbae9d1c6f1fa

Resolution of the online meeting of Russian experts on the EMPEROR-REDUCED trial

Autor: G. P. Arutyunov, A. G. Arutyunov, E. I. Tarlovskaya, A. S. Ametov, N. G. Vinogradova, A. A. Garganeeva, M. G. Glezer, I. V. Zhirov, M. V. Ilyin, N. A. Koziolova, A. O. Konradi, A. Yu. Lebedeva, Yu. M. Lopatin, S. V. Nedogoda, V. V. Salukhov, M. Yu. Sitnikova, S. N. Tereshchenko, S. N. Tolstov, Yu. Sh. Khalimov, N. R. Khasanov, A. I. Chesnikova, V. Giga, M. Paсker

Publikováno v: Российский кардиологический журнал, Vol 25, Iss 11 (2020)

At the online meeting held on September 3, 2020, the results of the international multicenter trial EMPEROR-REDUCED were considered. Number of proposals and recommendations for the further study of cardiovascular and renal effects of empagliflozin an

Externí odkaz: https://doaj.org/article/a3a3f78f9f8848ac8a0840a2dddb6e4c